Philipp Stämpfli
Neuroscientist
Data updated
Research Footprint
Philipp Stämpfli appears in 8 tracked papers (2016–2021), most studied alongside LSD, Psilocybin and Placebo, across Neuroimaging & Brain Measures, Healthy Volunteers and Interpersonal Functioning & Social Connectedness.
Most-cited paper: Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor (408 citations).
Frequent co-authors: Katrin Preller, Franz Vollenweider and Erich Seifritz.
Background & Research
P Stämpfli is a neuroscientist whose work centres on human neuroimaging studies of serotonergic psychedelics, with a focus on receptor-level mechanisms and network dynamics underlying altered states of consciousness. Their contributions emphasise multimodal imaging and advanced connectivity analyses to characterise how 5-HT2A (and related serotonergic) receptor stimulation by compounds such as LSD and psilocybin changes brain-wide and thalamic connectivity, effective connectivity patterns, and electrophysiological indices of prediction error processing.
Stämpfli has been involved in studies using fMRI, simultaneous EEG–fMRI and dynamic causal modelling in healthy volunteer cohorts to probe both basic mechanisms and cognitive/behavioural consequences of psychedelic administration. Key projects attributed to them include work demonstrating that LSD-induced alterations in global and thalamic connectivity are attributable to 5-HT2A receptor activity; analyses of effective connectivity changes under LSD; investigations of serotonergic modulation of social exclusion processing; LSD-related changes in social adaptation to similar opinions; and a simultaneous EEG–fMRI study showing psilocybin-induced aberrant prediction-error processing to tactile mismatches. Methodologically, their profile reflects expertise in connectivity modelling, receptor-pharmacology-informed neuroimaging, and translational approaches linking neural dynamics to social and perceptual processes.
Key Impact
Notable for neuroimaging research elucidating 5-HT2A-mediated mechanisms of LSD- and psilocybin-induced altered states and their effects on connectivity and social cognition.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Philipp Stämpfli is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →